Clinical-pathologic features of EAE-affected mice
. | Disease incidence, no./no. total (%) . | Disease onset, d after immunization (range) . | Mean maximum neurologic score (range) . | Cumulative disease score . | Demyelination score (range) . | Macrophages, cells/mm2 (range) . | CD3+, cells/mm2 (range) . |
|---|---|---|---|---|---|---|---|
| Controls | 6/6 (100) | 9.8 ± 1.0 (9-11) | 3.9 ± 0.9 (2-5) | 149.0 ± 46.8 | 3.8 ± 1.3 (2-6) | 94.8 ± 34.5 (40-190) | 146.2 ± 35.7 (71-200) |
| Treated, d +3 and d +8 | 15/15 (100) | 10.1 ± 1.2 (9-13) | 3.1 ± 1.1 (1-5) | 101.2 ± 48.6† | 1.9 ± 1.2† (1-5) | 52.7 ± 27.2† (20-134) | 54.7 ± 21.3† (22-103) |
| Treated, d +24 | 6/6 (100) | 10.0 ± 0.9 (9-11) | 4.0 ± 0.6 (3-5) | 150.7 ± 49.7 | 3.2 ± 1.4 (1-6) | 89.9 ± 26.9 (42-132) | 107.7 ± 25.4 (73-155) |
| Controls | 8/8 (100) | 10.4 ± 0.6 (9-12) | 3.2 ± 0.4 (2.5-4) | 122.8 ± 17.8 | 6.1 ± 1.86 (2-8) | 110.0 ± 21.9 (65-138) | 123.8 ± 22.0 (71-158) |
| Treated, d + 10 | 7/8 (88) | 9.7 ± 1.8 (7-14) | 2.8 ± 0.3 (2-3.5) | 98.1 ± 14.3* | 2.5 ± 1.3† (1-5) | 52.7 ± 15.0† (34-87) | 74.7 ± 17.4† (51-112) |
| Treated, d + 15 | 7/8 (88) | 10.3 ± 0.9 (9-12) | 2.8 ± 0.3 (2-3.5) | 94.2 ± 15.3 | 3 ± 2.2* (1-8) | 66.9 ± 12.7† (48-88) | 84.9 ± 19.9† (58-117) |
. | Disease incidence, no./no. total (%) . | Disease onset, d after immunization (range) . | Mean maximum neurologic score (range) . | Cumulative disease score . | Demyelination score (range) . | Macrophages, cells/mm2 (range) . | CD3+, cells/mm2 (range) . |
|---|---|---|---|---|---|---|---|
| Controls | 6/6 (100) | 9.8 ± 1.0 (9-11) | 3.9 ± 0.9 (2-5) | 149.0 ± 46.8 | 3.8 ± 1.3 (2-6) | 94.8 ± 34.5 (40-190) | 146.2 ± 35.7 (71-200) |
| Treated, d +3 and d +8 | 15/15 (100) | 10.1 ± 1.2 (9-13) | 3.1 ± 1.1 (1-5) | 101.2 ± 48.6† | 1.9 ± 1.2† (1-5) | 52.7 ± 27.2† (20-134) | 54.7 ± 21.3† (22-103) |
| Treated, d +24 | 6/6 (100) | 10.0 ± 0.9 (9-11) | 4.0 ± 0.6 (3-5) | 150.7 ± 49.7 | 3.2 ± 1.4 (1-6) | 89.9 ± 26.9 (42-132) | 107.7 ± 25.4 (73-155) |
| Controls | 8/8 (100) | 10.4 ± 0.6 (9-12) | 3.2 ± 0.4 (2.5-4) | 122.8 ± 17.8 | 6.1 ± 1.86 (2-8) | 110.0 ± 21.9 (65-138) | 123.8 ± 22.0 (71-158) |
| Treated, d + 10 | 7/8 (88) | 9.7 ± 1.8 (7-14) | 2.8 ± 0.3 (2-3.5) | 98.1 ± 14.3* | 2.5 ± 1.3† (1-5) | 52.7 ± 15.0† (34-87) | 74.7 ± 17.4† (51-112) |
| Treated, d + 15 | 7/8 (88) | 10.3 ± 0.9 (9-12) | 2.8 ± 0.3 (2-3.5) | 94.2 ± 15.3 | 3 ± 2.2* (1-8) | 66.9 ± 12.7† (48-88) | 84.9 ± 19.9† (58-117) |